<DOC>
	<DOC>NCT01730534</DOC>
	<brief_summary>This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.</brief_summary>
	<brief_title>Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Provision of informed consent prior to any study specific procedures Female or male aged â‰¥40 years Diagnosed with Type 2 Diabetes High Risk for Cardiovascular events Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time Chronic cystitis and/or recurrent urinary tract infections Pregnant or breastfeeding patients</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase IIIb</keyword>
	<keyword>T2DM</keyword>
	<keyword>cardiovascular events</keyword>
</DOC>